藥物發現外包市場規模、佔有率、成長分析、按工作流程、按治療領域、按地區 - 行業預測，2024-2031 年

2022 年全球藥物發現外包市場規模約 34 億美元，預測期內（2024-2031 年）複合年成長率為 7.2%，從2023 年的 36 億美元，預計 2031 年將達到 63 億美元。

由於對具有成本效益和高效的藥物開發流程的需求不斷增加，全球藥物發現外包市場正在顯著成長。製藥公司正在轉向外包來獲取專業知識、先進技術和可擴展的資源。這種轉變使公司能夠專注於其核心競爭力，同時降低營運成本並加快藥物發現時間表。此外，隨著藥物開發變得更加複雜和監管要求變得更加嚴格，公司擴大與委外研發機構(CRO) 合作，以提供創新的解決方案和全面的服務。由於大型製藥公司和研究機構的存在，北美和歐洲等研究地區佔據了市場主導地位。然而，市場也面臨著資料隱私問題、智慧財產權問題以及外包合作夥伴提供的服務品質不一致等挑戰，這可能會阻礙成長。儘管存在這些挑戰，技術進步和生物技術投資的增加預計將在市場上創造新的機會。

目錄

介紹

• 研究目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 二手資料來源和主要資料來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 監管分析
• 案例研究分析

藥物發現外包市場：依工作流程分類

• 市場概況
• 目標識別和篩檢
• 目標檢驗和功能資訊學
• 潛在客戶識別和候選最佳化
• 臨床前開發
• 其他相關工作流程

藥物發現外包市場：依治療領域

• 市場概況
• 呼吸系統
• 疼痛和麻醉
• 腫瘤學
• 眼科
• 血液學
• 心血管
• 內分泌
• 胃腸道
• 免疫調節
• 抗感染
• 中樞神經系統
• 皮膚科
• 泌尿生殖系統

藥物發現外包市場：按藥物類型

• 市場概況
• 低分子
• 大分子（生物製藥）

藥物發現外包市場：依服務類型

• 市場概況
• 化學服務
• 生物服務

藥物發現外包市場：依最終用戶分類

• 市場概況
• 製藥和生物技術公司
• 學術機構
• 其他

藥物發現外包市場規模：按地區分類

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Charles River Laboratories International, Inc.
• WuXi AppTec Co., Ltd.
• Laboratory Corporation of America Holdings（LabCorp）
• Evotec SE
• Covance Inc.
• Thermo Fisher Scientific Inc.
• Eurofins Scientific
• Pharmaron Beijing Co., Ltd.
• Syngene International Ltd.
• Genscript Biotech Corporation
• ChemPartner
• Jubilant Biosys Ltd.
• ICON plc
• QuintilesIMS（IQVIA）
• Cambrex Corporation
• Viva Biotech
• Domainex Ltd.
• Curia Global, Inc.（formerly Albany Molecular Research, Inc.）
• Tecan Group Ltd.
• Shanghai Medicilon Inc.

Global Drug Discovery Outsourcing Market size was valued at around 3.4 billion in 2022 and is expected to rise from USD 3.6 billion in 2023 to reach a value of USD 6.3 billion by 2031, at a CAGR of 7.2% over the forecast period (2024-2031).

The Global Drug Discovery Outsourcing Market is witnessing significant growth, driven by an increasing demand for cost-effective and efficient drug development processes. Pharmaceutical companies are increasingly leveraging outsourcing to access specialized expertise, advanced technologies, and scalable resources. This shift allows firms to focus on their core competencies while reducing operational costs and expediting the drug discovery timeline. Additionally, the rising complexity of drug development, coupled with stringent regulatory requirements, is pushing companies to collaborate with Contract Research Organizations (CROs) that offer innovative solutions and comprehensive services. Regions like North America and Europe dominate the market, owing to the presence of major pharmaceutical companies and research institutions. However, the market also faces challenges such as data privacy concerns, intellectual property issues, and the variability in the quality of services provided by outsourcing partners, which could potentially hinder growth. Despite these challenges, advancements in technology and increasing investments in biotech are expected to create new opportunities within the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Drug Discovery Outsourcing Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Drug Discovery Outsourcing Market Segmental Analysis

Global Drug Discovery Outsourcing Market is segmented by Workflow, Therapeutics Area, Drug Type, Service Type, End User, and region. Based on Workflow, the market is segmented into Target Identification & Screening, Target Validation & Functional Informatics, Lead Identification & Candidate Optimization, Preclinical Development, and Other Associated Workflow. Based on Therapeutics Area, the market is segmented into Respiratory system, Pain and Anesthesia, Oncology, Ophthalmology, Hematology, Cardiovascular, Endocrine, Gastrointestinal, Immunomodulation, Anti-infective, Central Nervous System, Dermatology, and Genitourinary System. Based on Drug Type, the market is segmented into Small Molecules, Large Molecules (Biopharmaceuticals). Based on Service Type, the market is segmented into Chemistry Services, Biology Services. Based on End User, the market is segmented into Pharmaceutical & Biotechnology companies, Academic Institutes, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Drug Discovery Outsourcing Market

Technological advancements are a pivotal driver of the Global Drug Discovery Outsourcing Market. The integration of cutting-edge technologies such as artificial intelligence (AI), machine learning, and big data analytics into drug discovery processes has revolutionized the landscape. These technologies enable faster data analysis, predictive modeling, and more accurate identification of potential drug candidates. By outsourcing to firms that specialize in these advanced methodologies, pharmaceutical companies can enhance their research efficiency, reduce time-to-market, and improve the overall success rate of drug development. Furthermore, advancements in automation and high-throughput screening techniques are allowing for more efficient laboratory processes, further supporting the trend toward outsourcing. As the drug discovery process becomes increasingly reliant on these technologies, the demand for specialized outsourcing services is expected to rise, driving market growth.

Restraints in the Global Drug Discovery Outsourcing Market

Data security concerns represent a significant restraint on the Global Drug Discovery Outsourcing Market. As pharmaceutical companies share sensitive research data and proprietary information with outsourcing partners, the risk of data breaches and unauthorized access becomes a pressing issue. Regulatory compliance requirements, such as the Health Insurance Portability and Accountability Act (HIPAA) and the General Data Protection Regulation (GDPR), impose stringent guidelines on data management and protection, complicating outsourcing arrangements. Any breach of confidentiality can lead to significant financial losses, legal repercussions, and reputational damage for pharmaceutical companies. Moreover, varying data protection laws across different countries add to the complexity, making it challenging for firms to ensure compliance. Consequently, companies may hesitate to fully embrace outsourcing, which can limit the market's growth potential.

Market Trends of the Global Drug Discovery Outsourcing Market

The increasing focus on personalized medicine is a notable trend shaping the Global Drug Discovery Outsourcing Market. As the healthcare industry shifts toward tailored treatments based on individual genetic profiles and specific patient needs, drug discovery processes must adapt accordingly. Outsourcing partners are increasingly required to develop innovative methodologies and technologies that facilitate the discovery of targeted therapies. This trend not only enhances the efficacy of drug development but also improves patient outcomes by ensuring that treatments are aligned with unique biological characteristics. The rise of biomarker research, genomic studies, and advanced analytics is driving collaboration between pharmaceutical companies and CROs, who are equipped to handle the complexities associated with personalized medicine. As this trend continues to gain momentum, the demand for specialized outsourcing services that can support the development of personalized therapies is expected to grow, influencing the overall dynamics of the market.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Regulatory Analysis
• Case Study Analysis

Drug Discovery Outsourcing Market, By Workflow

• Market Overview
• Target Identification & Screening
• Target Validation & Functional Informatics
• Lead Identification & Candidate Optimization
• Preclinical Development
• Other Associated Workflow

Drug Discovery Outsourcing Market, By Therapeutics Area

• Market Overview
• Respiratory system
• Pain and Anesthesia
• Oncology
• Ophthalmology
• Hematology
• Cardiovascular
• Endocrine
• Gastrointestinal
• Immunomodulation
• Anti-infective
• Central Nervous System
• Dermatology
• Genitourinary System

Drug Discovery Outsourcing Market, By Drug Type

• Market Overview
• Small Molecules
• Large Molecules (Biopharmaceuticals)

Drug Discovery Outsourcing Market, By Service Type

• Market Overview
• Chemistry Services
• Biology Services

Drug Discovery Outsourcing Market, By End User

• Market Overview
• Pharmaceutical & Biotechnology companies
• Academic Institutes
• Others

Drug Discovery Outsourcing Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Charles River Laboratories International, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Laboratory Corporation of America Holdings (LabCorp)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evotec SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Covance Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmaron Beijing Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syngene International Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genscript Biotech Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ChemPartner
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Biosys Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICON plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QuintilesIMS (IQVIA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cambrex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viva Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Domainex Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curia Global, Inc. (formerly Albany Molecular Research, Inc.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tecan Group Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Medicilon Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments